Parse Biosciences launches a fully integrated immune repertoire and whole transcriptome analysis workflow in its data analysis platform, Trailmaker.

The NCCN guidelines now include MammaPrint for identifying HR+/HER2- early-stage breast cancer patients who may benefit from ...